Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a ...

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for ...

Patients with predominantly cranial vs isolated extracranial GCA phenotypes present with different patterns of arterial involvement on 18F-FDG PET-CT scans.

Patients with LVV and IBD present with distinct clinical characteristics, including earlier onset and more severe vascular involvement.

AbbVie’s Rinvoq (upadacitinib) has been granted marketing authorisation by the European Commission (EC) to treat giant cell ...

The European Commission (EC) has granted marketing authorisation for AbbVie's once-a-day treatment Rinvoq (upadacitinib) 15mg ...

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis.

The European Commission (EC) has granted marketing authorization to Rinvoq (upadacitinib; 15mg, once daily), from US pharma ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...